,

Future of Medicine, Episode 2: Gene Editing Nears Approval, AI Classifies Blood Cancer and a Voice from the Brain (Week 47, 2026)

Ampullen und Spritzen auf blauem Hintergrund

Welcome to the second episode of “Future of Medicine”. Once again we look at four fields shaping tomorrow’s medicine: gene therapy, artificial intelligence in cancer care, longevity and biotechnology, and technology that makes life noticeably easier. For each field there is one piece of news and one company in profile.

In short: the first gene-editing therapy that works directly inside the body is approaching a US approval decision – for hereditary angioedema. An AI classifies blood cancers very accurately from chemical marks on DNA. A drug that throttles production of the Alzheimer’s protein tau shows signs of slower decline after two years. And brain implants are giving paralysed people back a voice that can even sing.

1. Gene therapy: the first in-body gene editor nears approval

What happened? On 12 November, US company Intellia Therapeutics of Cambridge, Massachusetts, summarised the status of its gene-editing therapy lonvo-z (lonvoguran ziclumeran) in an investor presentation. It targets hereditary angioedema (HAE), a rare inherited disease in which the skin, abdomen or airways suddenly swell, sometimes life-threateningly. The trigger is an excess of the messenger substance bradykinin. Lonvo-z is given once as an infusion. Lipid nanoparticles carry the CRISPR gene editor to the liver, where it switches off the KLKB1 gene, so less bradykinin is produced. The US Food and Drug Administration (FDA) is reviewing the application with priority and aims to decide by 10 March 2027; according to the company, the agency does not plan an advisory committee.

The basis is the phase 3 HAELO trial with 80 participants aged 16 and over: 52 received lonvo-z and 28 a placebo. From week 5 to 28, attacks were 87 per cent less frequent with lonvo-z. 62 per cent remained free of attacks and of preventive long-term therapy, compared with 11 per cent in the placebo group. The most common side effects were infusion reactions; among 93 treated people, Intellia reports two serious events.

What does it mean? If approved, lonvo-z would be the first approved gene-editing therapy that works directly in the body – without removing and returning cells as with Casgevy. Open questions remain on how long the effect lasts over many years and on the long-term safety of a permanent change to DNA. Background: Gene Editing Inside the Body: Lonvo-z for Hereditary Angioedema Nears US Approval.

Company profile: nChroma Bio

The Boston company was formed in December 2024 from the merger of Chroma Medicine and Nvelop Therapeutics and launched with 75 million US dollars in financing. Its CEO is Jeff Walsh. The technology: epigenetic editing. Instead of cutting DNA, a “blunt” CRISPR tool places chemical marks (methyl groups) at a site and thereby silences the gene.

Its first drug, CRMA-1001, is intended to permanently silence the genetic material of the hepatitis B virus in liver cells. On 28 January 2026 the first person was dosed in a phase 1/2 trial (NCT07200193) with sites including Hong Kong. In mice, the viral protein HBsAg fell more than a thousandfold for at least six months, according to the company. Open questions: human data are still pending; the company expects them at the end of 2026. A cure for hepatitis B is so far a goal, not a result. How base, prime and epigenetic editing differ: Beyond the Gene Scissors: Base, Prime and Epigenetic Editing Reach the Clinic.

2. AI and cancer: reading blood cancer from DNA patterns

What happened? At the annual meeting of the Association for Molecular Pathology (AMP) in Seattle, the AI model ALMA 3 was presented on 13 November, developed by ALMA Genomics with partners including the University of Pennsylvania. It reads methylation – chemical marks on DNA that form a typical pattern for each cell type – and uses it to classify blood and lymphatic cancers. It was trained on more than 110,000 samples. In independent testing across 81 subtypes it detected 99.5 per cent of tumours (sensitivity); when it named a specific subtype, it was correct in 90.9 per cent of cases (positive predictive value). A team from Memorial Sloan Kettering Cancer Center also showed that AI on lung cancer slides could have spared a rapid EGFR mutation test in 26 of 80 cases.

What does it mean? Precise classification of blood cancer determines treatment and today requires many separate tests. A single methylation profile could simplify this. For now these are conference presentations.

Company profile: Lunit

The company is based in Seoul, South Korea, and listed on the KOSDAQ exchange. Its Lunit INSIGHT software analyses mammograms (2D and 3D) and chest X-rays and marks suspicious areas for radiologists; the Lunit SCOPE line analyses tissue slides, for example to assess immune markers such as PD-L1. The mammography software and a chest X-ray triage tool have FDA clearance, and several products carry the CE mark. Lunit has acquired the breast imaging company Volpara.

At the RSNA radiology meeting in Chicago (29 November to 3 December), Lunit will present 17 studies, 15 of them on breast cancer – including a comparison of four FDA-cleared AI products. Open questions: much of the data comes from the company itself or from retrospective analyses. What counts are large, independent screening studies; the AI assists, the diagnosis remains with humans. More: Mammography and AI in Pathology: When Algorithms Read Tissue Samples.

3. Longevity and biotechnology: a tau brake against Alzheimer’s

What happened? On 17 November, at the CTAD Alzheimer’s conference, Biogen presented two-year data on diranersen (BIIB080). The drug is an antisense molecule: it intercepts the blueprint (mRNA) for tau, a protein that clumps inside nerve cells in Alzheimer’s disease, and so reduces its production. It is injected into the spinal fluid every three to six months. The phase 2 CELIA trial enrolled 416 people with mild cognitive impairment or mild dementia due to Alzheimer’s. In the group receiving 60 milligrams every six months, decline on the CDR-SB dementia scale was 26 per cent slower at week 76 and 38 per cent slower at week 96 than in the comparison group. Biogen saw no new safety signals.

What does it mean? Approved Alzheimer’s antibodies target amyloid; tau would be a second line of attack against one of the most common diseases of ageing. However, the figures come from a press release, and the second year was open-label: the comparison group was able to switch after week 76. A phase 3 trial must confirm the effect. More on the disease: Alzheimer’s disease.

Company profile: Insilico Medicine

Founded in 2014 and based in the US and Hong Kong, the company designs drug candidates with generative AI (its Pharma.AI platform); its founder and co-CEO is the ageing researcher Alex Zhavoronkov. At the end of December 2025 Insilico listed in Hong Kong, raising around 2.28 billion Hong Kong dollars (about 293 million US dollars). Its pipeline includes around 30 programmes; partners include Lilly and Sanofi. Most advanced is rentosertib, an inhibitor of the enzyme TNIK for idiopathic pulmonary fibrosis. After a 12-week phase 2a trial with 71 patients in China (published in Nature Medicine in 2025), a phase 3 trial has been running since July 2026.

Of interest for longevity: in September Insilico reported in Nature Biotechnology that in 42 participants of this trial, six so-called proteomic clocks in the blood indicated a younger biological age after four weeks – by about 2.7 to 3.5 years in one dose group. Open questions: the group is small, and the clocks may simply reflect improvement of the lung disease. None of the company’s drugs is approved yet. Related: First in Humans: Cellular Rejuvenation by Gene Therapy Begins in the Eye.

4. Technology for a better life: a voice straight from the brain

In focus: At the Society for Neuroscience meeting in Washington (14 to 18 November), three teams presented brain-computer interfaces for communication. Maitreyee Wairagkar of UC Davis showed a synthetic voice that also reproduces intonation; one participant was even able to sing a musical scale with it. Daniel Rubin of Massachusetts General Hospital reported on a person with complete locked-in syndrome who has communicated independently through an interface for more than a year. Chethan Pandarinath (Georgia Tech and Emory) presented a portable system that translates brain signals into text on an iPhone.

What does it mean? For people with ALS or severe paralysis, more natural communication suitable for everyday life is moving closer. But these are conference presentations involving individual participants. That the path is not straightforward is shown by US company Synchron: according to STAT on 13 November, it has paused trials of its second-generation implant – not for safety reasons, the company says.

Company profile: Precision Neuroscience

The company was founded in New York in 2021. Its “Layer 7” is a very thin electrode film with hundreds of tiny electrodes that rests on the surface of the brain without penetrating tissue; it is inserted through a narrow slit in the skull. In 2025 Layer 7 received FDA 510(k) clearance for recording and stimulating on the brain surface for up to 30 days. According to the company, the system has been used in more than 100 clinical study patients. On 16 November Precision announced a partnership with the ALS organisation Team Gleason: people with ALS and their families are to help shape development.

Open questions: the clearance covers temporary use only. A permanently implantable, wireless system is still in development and is an investigational device. In Episode 1 we featured an implant that enables walking by thought; for a longer view see Medicine in 25 Years.

Frequently asked questions

How does in-body gene editing differ from Casgevy?

With Casgevy, blood stem cells are removed, modified in the lab and returned after chemotherapy. Lonvo-z, by contrast, is given as an infusion and modifies liver cells directly in the body. That is simpler, but the change is just as permanent.

Can AI already make a cancer diagnosis?

No. AI tools are being tested and in some cases already used as support, for example in mammography screening. Diagnosis and treatment decisions remain with doctors. The blood cancer model presented here is still being validated.

Can pills lower biological age?

That has not been shown. Biological clocks are research tools; a younger reading does not mean a longer healthy life. The best evidence is for exercise and a balanced diet. No drug is approved to slow ageing.

Note: This article is for general information only and does not replace medical advice. It is not investment advice. Company statements are marked as such; sources as of 19 November 2026.

Sources

AnzeigeAnzeige: WUNDREPAIR – Pflege aus Pflanzen

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.